Payment overview · 2025
General Payments
$87,794.75
220 reported records · 34 companies
Healthcare provider profile · identity verified
Brendan W Bauer, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SHEFFIELD VILLAGE, OH · NPI 1245202043
Verified facts
What the public records show
CMS Open Payments records show Brendan W Bauer, MD received $87,794.75 in general payments during 2025 across 220 reported records.
EMD Serono, Inc. accounted for 50.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Hizentra, Mavenclad, Nayzilam, Nuplazid, Nurtec Odt, Qulipta, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Hizentra by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mavenclad as an associated drug or biological on 3542 records involving 766 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mavenclad by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $44,509.36 | 50.7% | 34 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $21,579.64 | 24.6% | 14 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $12,683.81 | 14.4% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $6,965.08 | 7.9% | 46 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $175.10 | 0.2% | 8 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $155.13 | 0.2% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $152.22 | 0.2% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $149.09 | 0.2% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $147.95 | 0.2% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.80 | 0.2% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $134.64 | 0.1% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $95.92 | 0.1% | 6 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $65.55 | 0.1% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.70 | 0.1% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $62.57 | 0.1% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $61.10 | 0.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.31 | 0.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.20 | 0.1% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $54.64 | 0.1% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $49.10 | 0.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $46.05 | 0.1% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $44.51 | 0.1% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $39.62 | 0.1% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.01 | 0.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $38.80 | 0.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.39 | 0.0% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$33.84 | 0.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.50 | 0.0% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$30.11 | 0.0% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $29.22 | 0.0% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.90 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.74 | 0.0% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.23 | 0.0% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $10.92 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $81,975.75 | 24 |
| Food and Beverage | $4,701.86 | 189 |
| Travel and Lodging | $873.23 | 2 |
| Education | $243.91 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $38,905.27 | 16 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $21,579.64 | 14 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $12,683.81 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $6,844.37 | 31 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $3,096.14 | 39 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $175.10 | 8 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $155.13 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $148.19 | 10 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $136.80 | 9 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $134.64 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $95.68 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $76.59 | 5 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $74.13 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $65.55 | 3 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $64.70 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $62.57 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $61.10 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $56.31 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $56.31 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $54.64 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $49.10 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $46.05 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $44.51 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $39.62 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $32.50 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $30.11 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $28.05 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $25.80 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $10.92 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $6.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Hizentra hizentra |
2025 | Hizentra | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mavenclad mavenclad |
2025 | Mavenclad | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 93 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Mavenclad open payments reported associated product |
CMS Open Payments — General Payments 3542 supporting records · 766 recipient NPIs · example record 1236867010 |
Mavenclad · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
93 | 24 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pregabalin | Pregabalin | 360 | 98 |
| Dexamethasone | Dexamethasone | 334 | 160 |
| Memantine Hcl | Memantine Hcl | 330 | 95 |
| Gabapentin | Gabapentin | 249 | 64 |
| Tizanidine Hcl | Tizanidine Hcl | 248 | 75 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 223 | 72 |
| Nortriptyline Hcl | Nortriptyline Hcl | 217 | 70 |
| Prednisone | Prednisone | 202 | 86 |
| Topiramate | Topiramate | 201 | 48 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 189 | 48 |
| Ropinirole Hcl | Ropinirole Hcl | 154 | 38 |
| Meloxicam | Meloxicam | 142 | 36 |
| Montelukast Sodium | Montelukast Sodium | 142 | 42 |
| Amantadine | Amantadine Hcl | 140 | 44 |
| Baclofen | Baclofen | 132 | 42 |
| Levetiracetam | Levetiracetam | 120 | 28 |
| Donepezil Hcl | Donepezil Hcl | 106 | 30 |
| Primidone | Primidone | 99 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 29 |
| Nurtec Odt | Rimegepant Sulfate | 93 | 24 |
| Tramadol Hcl | Tramadol Hcl | 93 | 32 |
| Clonazepam | Clonazepam | 90 | 17 |
| Memantine Hcl Er | Memantine Hcl | 89 | 28 |
| Piroxicam | Piroxicam | 85 | 22 |
| Oxcarbazepine | Oxcarbazepine | 80 | 23 |
| Zonisamide | Zonisamide | 79 | 17 |
| Trazodone Hcl | Trazodone Hcl | 68 | 16 |
| Modafinil | Modafinil | 67 | 16 |
| Atomoxetine Hcl | Atomoxetine Hcl | 64 | 16 |
| Meclizine Hcl | Meclizine Hcl | 64 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 24 |
| Lorazepam | Lorazepam | 52 | 19 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Diazepam | Diazepam | 49 | 17 |
| Doxepin Hcl | Doxepin Hcl | 49 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | 14 |
| Propranolol Hcl | Propranolol Hcl | 46 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 11 |
| Bupropion Xl | Bupropion Hcl | 44 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 42 | 12 |
| Lamotrigine | Lamotrigine | 40 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 39 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 37 | suppressed |
| Ubrelvy | Ubrogepant | 37 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 35 | suppressed |
| Xcopri | Cenobamate | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Glycopyrrolate | Glycopyrrolate | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | suppressed |
| Perphenazine | Perphenazine | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 14 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Acetazolamide | Acetazolamide | 24 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 23 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 21 | suppressed |
| Entacapone | Entacapone | 21 | suppressed |
| Kesimpta Pen | Ofatumumab | 21 | suppressed |
| Nayzilam | Midazolam | 21 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Fingolimod | Fingolimod Hcl | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Qulipta | Atogepant | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 13 | suppressed |
| Northera | Droxidopa | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Mavenclad | Cladribine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87,794.75 · 220 records | EMD Serono, Inc. | ACTHAR, AMYVID, AUSTEDO XR, Azstarys, BOTOX, BRIUMVI, Briviact, GOMEKLI, HORIZANT, HYQVIA, Hizentra, INGREZZA, KESIMPTA, KISUNLA, Leqembi, Mavenclad, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, QUTENZA, Qelbree, REXULTI, Rystiggo, Sunosi, Symbravo, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA, Zilbrysq | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Hizentra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error